News Interpace Biosciences, Inc.

Stocks

IDXG

US46062X4025

Healthcare Facilities & Services

Market Closed - OTC Markets 19:35:24 30/10/2026 +04			5-day change	1st Jan Change
5.592 ^USD	-2.23%		-13.96%	-9.08%

10-15	Interpace Biosciences, Inc. Provides Preliminary, Unaudited Earnings Guidance for the Third Quarter Ended September 30, 2026	CI
08-11	Interpace Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

All News

Mentions Relevance

10-15	Interpace Biosciences, Inc. Provides Preliminary, Unaudited Earnings Guidance for the Third Quarter Ended September 30, 2026	CI
08-27	Interpace Biosciences Announces Reverse Stock Split to Support Proposed Nasdaq Uplisting	AQ
08-11	Interpace Biosciences Announces Second Quarter 2026 Financial and Business Results	AQ
08-11	Interpace Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-13	Interpace Biosciences Announces First Quarter 2026 Financial and Business Results	AQ
05-13	Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-31	Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results	AQ
03-31	Interpace Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
01-20	Interpace Biosciences Announces Preliminary and Unaudited Revenue Results for the Year 2025	CI
01-20	Interpace Biosciences, Inc. Provides Preliminary Unaudited Revenue Guidance for the Full Year of 2025 and Initiates Revenue Guidance for the Full Year of 2026	CI
01-20	Interpace Biosciences Announces Preliminary 2025 Revenue, 2026 Revenue Guidance and Simplification of Capital Structure	AQ
12-03	Interpace Biosciences Announces Early Repayment of Debt to BroadOak Capital Partners	CI
12-03	Interpace Biosciences Announces Early Repayment of Debt to BroadOak Capital Partners	AQ
11-13	Interpace Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-13	Interpace Biosciences Q3 revenue down	RE
11-13	Interpace Biosciences Announces Third Quarter 2025 Financial and Business Results	AQ
16/09/25	Interpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association Annual Meeting	AQ
15/09/25	Interpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association® (ATA) Annual Meeting	AQ
08/08/25	Interpace Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
08/08/25	Interpace Biosciences Announces Second Quarter 2025 Financial and Business Results	AQ
09/05/25	Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
09/05/25	Interpace Biosciences Announces First Quarter 2025 Financial and Business Results	AQ
09/05/25	Interpace Biosciences, Inc. Provides Revenue Guidance for the Full-Year 2025	CI
25/04/25	Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk	AQ
01/04/25	Interpace Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI